Colorectal Neoplasms
650
73
95
303
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
80 trials with published results (12%)
Research Maturity
303 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.7%
63 terminated out of 650 trials
82.8%
-3.8% vs benchmark
10%
66 trials in Phase 3/4
26%
80 of 303 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 303 completed trials
Clinical Trials (650)
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
AI-Based Stool Image Analysis for Colorectal Neoplasia Risk Assessment
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Preventing Early-Onset Colorectal Cancer in the VA
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
A Novel Clinical Decision Support Tool to Predict Submucosal Invasive Cancer Within Large Non-Pedunculated Colorectal Polyps
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Physical Activity Centers Empowerment
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors